NASDAQ · LXEO
Healthcare · Biotechnology
$3.06
Down-$0.07 (-2.24%)
Updated Oct 30, 2026, 8:45 AM
SID Score
4.2/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · LXEO
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 29, 2026
LXEO closed at $3.06 after 21 trading sessions, down 15.47% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 29, 2026 | $3.16 | $3.375 | $3.05 | $3.06 | 1.05M |
| Oct 28, 2026 | $2.85 | $3.14 | $2.78 | $3.13 | 1.2M |
| Oct 27, 2026 | $2.71 | $2.935 | $2.65 | $2.87 | 2.68M |
| Oct 26, 2026 | $2.80 | $2.825 | $2.675 | $2.70 | 1.16M |
| Oct 23, 2026 | $2.87 | $2.965 | $2.73 | $2.80 | 619.38K |
| Oct 22, 2026 | $2.98 | $3.12 | $2.89 | $2.89 | 492.47K |
| Oct 21, 2026 | $3.03 | $3.09 | $2.97 | $3.00 | 1.08M |
| Oct 20, 2026 | $2.76 | $3.055 | $2.71 | $3.02 | 1.28M |
| Oct 19, 2026 | $2.65 | $2.81 | $2.55 | $2.76 | 1.86M |
| Oct 16, 2026 | $2.75 | $2.84 | $2.63 | $2.64 | 2.51M |
| Oct 15, 2026 | $2.66 | $2.83 | $2.61 | $2.76 | 1.3M |
| Oct 14, 2026 | $2.70 | $2.785 | $2.56 | $2.63 | 1.94M |
| Oct 13, 2026 | $3.09 | $3.09 | $2.74 | $2.74 | 1.59M |
| Oct 12, 2026 | $3.22 | $3.22 | $3.04 | $3.04 | 1.05M |
| Oct 9, 2026 | $3.21 | $3.34 | $3.115 | $3.23 | 961.38K |
| Oct 8, 2026 | $3.27 | $3.28 | $3.1113 | $3.21 | 2.55M |
| Oct 7, 2026 | $3.27 | $3.465 | $3.22 | $3.31 | 1.2M |
| Oct 6, 2026 | $3.43 | $3.43 | $3.17 | $3.30 | 1.54M |
| Oct 5, 2026 | $3.56 | $3.655 | $3.37 | $3.41 | 1.86M |
| Oct 2, 2026 | $3.66 | $3.6885 | $3.495 | $3.53 | 2.59M |
| Oct 1, 2026 | $3.38 | $3.68 | $3.2953 | $3.62 | 2.89M |
The latest Smart Investors Daily articles mentioning LXEO.
Company
Market Activity
Research & News
LXEO research
Company profile and research snapshot.
Lexeo Therapeutics Inc is a clinical-stage genetic medicines company committed to transforming healthcare by applying pioneering science to fundamentally alter how diseases are treated. The company focuses on preclinical and clinical stage gene therapies, specifically hereditary and acquired diseases with high unmet needs, which represent its sole business segment.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 23, 2026 | Leerink Partners | Outperform | — |
| Jun 25, 2026 | JP Morgan | Overweight | — |
| May 11, 2026 | Chardan Capital | Buy | — |
| Jan 13, 2026 | Chardan Capital | Buy | — |
| Jan 13, 2026 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
Yahoo · Oct 25, 2026
Lexeo Therapeutics (NASDAQ:LXEO) outlined upcoming clinical and regulatory milestones for its gene therapy programs in Friedreich’s ataxia cardiomyopathy and PKP2-associated arrhythmogenic cardiomyopathy during the Chardan Healthcare Conference. Chief Financial Officer Lou Tamayo said the clinical-
SeekingAlpha · Oct 24, 2026
2026-10-24. The following slide deck was published by Lexeo Therapeutics, Inc.
Yahoo · Oct 24, 2026
Lexeo Therapeutics (NASDAQ:LXEO) outlined its approach to evaluating LX2020, an investigational AAVrh10-based gene therapy for PKP2-associated arrhythmogenic cardiomyopathy, or ACM, ahead of an expected clinical and regulatory update later this quarter. CEO Nolan Townsend said PKP2 ACM is a serious
SeekingAlpha · Oct 21, 2026
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning LXEO.
